iCAD acquires VuCOMP’s cancer detection portfolio
iCAD, a Nashua, N.H.-based cancer detection and radiation therapy technology company, announced this week that it has completed its acquisition of the VuCOMP cancer detection portfolio.
The acquisition includes VuCOMP’s M-Vu computer aided detection (CAD) technology platform, a library of related data, key VuCOMP personnel, and preexisting customers.
Ken Ferry, iCAD CEO, said in a statement that the deal is a big step forward for the company.
“This acquisition strongly complements iCAD’s strategy and will help accelerate our efforts to bring new and innovative cancer detection and workflow solutions to market, particularly as we prepare to launch our tomosynthesis cancer detection solutions,” Ferry said. “The addition of VuCOMP’s leading researchers and engineers to the iCAD team also represents an important resource for our deep learning technology initiatives aimed at creating improved solutions to help healthcare providers detect cancer early and positions us to maintain and expand our leadership position in the industry in the years ahead.”
According to the company’s statement, iCAD will provide support to VuCOMP M-Vu customers and offer them additional iCAD products and services.
iCAD had previously purchased VuCOMP’s M-Vu Breast Density software back in April 2015.
Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.